A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease

Status:
Completed

Trial end date:
2020-03-01

Target enrollment:

Participant gender:

This is a multicenter, randomized, double-blind, placebo-controlled clinical trial in subjects with NAFLD and NASH.

Phase 2

Can-Fite BioPharma